BioSpace News Archive

TCR2 Therapeutics Inc. announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 9,600 shares of TCR2’s common stock to 3 new non-executive employees.

Ophirex, Inc., a public benefit biotechnology company, announced the successful completion of a $37 million Series B financing, led by AXA IM Prime Impact Master Fund I SCA SICAV-RAIF.

Acorda Therapeutics, Inc. announced that on December 31, 2022 it entered into a new long-term global supply agreement with Catalent for the manufacture of INBRIJA at its Center of Excellence for Spray Dried Dispersions in Boston where Catalent will continue to manufacture INBRIJA through 2030.

Palvella Therapeutics, Inc., a late clinical-stage biopharmaceutical company whose vision is to become the leading rare disease company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases in indications for which there are no FDA-approved therapies, announced the initial closing of its Series D financing of up to $37.7 million.

Bruker Corporation announced the acquisition of ACQUIFER Imaging GmbH, a pioneer in big-data management solutions for bioimaging and high-content microscopy.

Immune-Onc Therapeutics, Inc., a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints announced the close of an additional $25 million through a Series B extension, for a total of $131 million in Series B financing.

Emergent BioSolutions Inc. announced that it has signed an indefinite-delivery, indefinite-quantity procurement contract with a maximum value up to $379.6 million to supply RSDL® for use by all branches of the U.S. military.

Geron Corporation, a late-stage clinical biopharmaceutical company, announced the pricing of an upsized underwritten public offering consisting of 55,876,297 shares of its common stock at a public offering price of $2.45 per share and pre-funded warrants to purchase 25,000,000 shares of its common stock.

Graphite Bio, Inc. announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel for sickle cell disease due to a serious adverse event in the first patient dosed with nula-cel, and the company’s conclusion that the event is likely related to study treatment.

Parker Health, a biotechnology company, names Philip McDonald, MD as the company’s first Chief Medical Officer.